EcoDrugPlus

Glutamate Ionotropic Receptor Kainate Type Subunit 2

Ensembl ID : ENSAPEG00000021384
Gene Symbol: GRIK2
2 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 3

Ensembl ID : ENSAPEG00000006019
Gene Symbol: GRIK3
2 Cross references
257 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 4

Ensembl ID : ENSAPEG00000013262
Gene Symbol: GRIK4
1 Cross references
247 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAPEG00000003749
Gene Symbol: GRIK5
1 Cross references
258 Possible Orthologues:

Glutamate Ionotropic Receptor Kainate Type Subunit 5

Ensembl ID : ENSAPEG00000009966
Gene Symbol: GRIK5
1 Cross references
263 Possible Orthologues:

Glutamate Metabotropic Receptor 2

Ensembl ID : ENSAPEG00000016990
Gene Symbol: GRM2
1 Cross references
210 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAPEG00000018246
Gene Symbol: GRM4
1 Cross references
200 Possible Orthologues:

Glutamate Metabotropic Receptor 4

Ensembl ID : ENSAPEG00000023066
Gene Symbol: GRM4
1 Cross references
214 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSAPEG00000011016
Gene Symbol: GRIA1A
1 Cross references
252 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1b

Ensembl ID : ENSAPEG00000004572
Gene Symbol: GRIA1B
1 Cross references
250 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSAPEG00000000922
Gene Symbol: GRIA2B
1 Cross references
247 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 3a

Ensembl ID : ENSAPEG00000004695
Gene Symbol: GRIA3A
1 Cross references
254 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).